SPRI Becomes Newest DATATRAK Connect™ CRO Partner

SPRI Becomes Newest DATATRAK Connect™ CRO Partner

CLEVELAND [December 3] /PRNewswire/ — DATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced its newest CRO Connect Partner, SPRI. SPRI Clinical Trials is a contract research organization that takes a hands-on approach to clinical trial design, planning and management.

"In the complex world of drug development, DATATRAK's unified platform provides our clients and our clinical teams alike a single location to review consolidated data. Combining CTMS, EDC, IWR, ePRO and randomization on a single platform provides a seamless solution that works well for a single trial or a global program. The robust platform, industry experienced teams and competitive costs all combine to make this partnership a natural fit for SPRI," said Amy Rigney, SPRI's President and Chief Operations Officer.

"We are proud to include SPRI in our growing list of DATATRAK Connect™ Partners," said Laurence P. Birch, DATATRAK's CEO and Chairman of the Board. "SPRI's clinical trial expertise, particularly for CNS disorders, oncology, infectious disease and endocrinology, provides true insight in the efficient delivery of clinical trials. DATATRAK provides a flexible solution, assisting SPRI in providing the right combination of technology and services to fit their customers' needs. We look forward to continuing to develop our partnership with SPRI in the mutual focus of optimization."

The DATATRAK Connect™ Partner Program is collaboration between synergic companies to accelerate the drug development process. The program allows for extended services offerings to cover all areas of the drug development process with the goal of reducing study costs and furthering business development objectives.

Join DATATRAK Thought Leaders:

Tweet: SPRI Newest #DATATRAK Connect Partner http://bit.ly/1eJN9rM

About SPRI

Founded in 1972 as a clinical research site, SPRI is a Clinical CRO that takes a hands-on approach to clinical trial planning, execution and management. Specializing in patient enrollment technologies and methods that have allowed for 98% of studies meeting enrollment milestones; SPRI focuses its attention on CNS, Oncology, Infectious Disease, Endocrinology, Women's Health and Vaccine studies from its offices in the United States, Russia, Ukraine, Belarus, and Georgia.  With 10 years of CRO experience, SPRI can confidently provide a flexible and scalable study regardless of size or complexity.

For more information on SPRI, please visit www.spriclinicaltrials.com.


DATATRAK International is a worldwide technology and services company delivering unified eClinical® solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit www.datatrak.com.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on November 14, 2013 announcing its results for the third quarter of 2013. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.


Lisa Pahl, Director Marketing, DATATRAK International, Inc., +1-979-393-9025


Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.